AEON Biopharma, Inc.
AEON
$0.88
$0.00-0.23%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.52% | -27.73% | -36.46% | -41.17% | -31.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.40% | -49.94% | -59.16% | -57.36% | -47.34% |
| Operating Income | 41.40% | 49.94% | 59.16% | 57.36% | 47.34% |
| Income Before Tax | -193.37% | -100.02% | 99.46% | 134.87% | 110.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -193.37% | -100.02% | 99.46% | 134.87% | 110.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -193.37% | -100.02% | 99.46% | 134.87% | 110.92% |
| EBIT | 41.40% | 49.94% | 59.16% | 57.36% | 47.34% |
| EBITDA | 41.48% | 50.04% | 59.26% | 57.46% | 47.43% |
| EPS Basic | -102.31% | -64.04% | 98.40% | 144.28% | 115.05% |
| Normalized Basic EPS | 99.69% | 93.60% | 90.41% | 92.42% | -75.82% |
| EPS Diluted | -102.31% | -64.14% | 98.40% | 144.28% | 115.05% |
| Normalized Diluted EPS | 99.69% | 93.62% | 90.42% | 92.43% | -75.79% |
| Average Basic Shares Outstanding | 1,732.42% | 1,184.26% | 570.70% | 48.09% | -58.52% |
| Average Diluted Shares Outstanding | 1,731.57% | 1,184.31% | 570.74% | 48.11% | -58.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |